Mechanism for Fetal Globin Gene Expression: Role of the Soluble Guanylate Cyclase-cGMP-dependent Protein Kinase Pathway

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2001 Feb 15

PMID 11172039

Citations 45

Authors

T Ikuta

S Ausenda

M D Cappellini

Affiliations

Soon will be listed here.

Abstract

Despite considerable concerns with pharmacological stimulation of fetal hemoglobin (Hb F) as a therapeutic option for the beta-globin disorders, the molecular basis of action of Hb F-inducing agents remains unclear. Here we show that an intracellular pathway including soluble guanylate cyclase (sGC) and cGMP-dependent protein kinase (PKG) plays a role in induced expression of the gamma-globin gene. sGC, an obligate heterodimer of alpha- and beta-subunits, participates in a variety of physiological processes by converting GTP to cGMP. Northern blot analyses with erythroid cell lines expressing different beta-like globin genes showed that, whereas the beta-subunit is expressed at similar levels, high-level expression of the alpha-subunit is preferentially observed in erythroid cells expressing gamma-globin but not those expressing beta-globin. Also, the levels of expression of the gamma-globin gene correlate to those of the alpha-subunit. sGC activators or cGMP analogs increased expression of the gamma-globin gene in erythroleukemic cells as well as in primary erythroblasts from normal subjects and patients with beta-thalassemia. Nuclear run-off assays showed that the sGC activator protoporphyrin IX stimulates transcription of the gamma-globin gene. Furthermore, increased expression of the gamma-globin gene by well known Hb F-inducers such as hemin and butyrate was abolished by inhibiting sGC or PKG activity. Taken together, these results strongly suggest that the sGC-PKG pathway constitutes a mechanism that regulates expression of the gamma-globin gene. Further characterization of this pathway should permit us to develop new therapeutics for the beta-globin disorders.

Citing Articles

Mathematical Modeling of Hydroxyurea Therapy in Individuals with Sickle Cell Disease.

Pandey A, Estepp J, Raja R, Guolian Kang , Ramkrishna D Pharmaceutics. 2022; 14(5).

PMID: 35631651 PMC: 9144420. DOI: 10.3390/pharmaceutics14051065.

GAPDH is involved in the heme-maturation of myoglobin and hemoglobin.

Tupta B, Stuehr E, Sumi M, Sweeny E, Smith B, Stuehr D FASEB J. 2021; 36(2):e22099.

PMID: 34972240 PMC: 9239731. DOI: 10.1096/fj.202101237RR.

Synthesis and pharmacological evaluation of pomalidomide derivatives useful for sickle cell disease treatment.

de Melo T, Dulmovits B, Dos Santos Fernandes G, de Souza C, Lanaro C, He M Bioorg Chem. 2021; 114:105077.

PMID: 34130111 PMC: 8387409. DOI: 10.1016/j.bioorg.2021.105077.

A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic.

Yasara N, Premawardhena A, Mettananda S Orphanet J Rare Dis. 2021; 16(1):114.

PMID: 33648529 PMC: 7919989. DOI: 10.1186/s13023-021-01757-w.

Sickle cell disease: progress towards combination drug therapy.

Pace B, Starlard-Davenport A, Kutlar A Br J Haematol. 2021; 194(2):240-251.

PMID: 33471938 PMC: 8282668. DOI: 10.1111/bjh.17312.

References

Ignarro L, Wood K . Activation of purified soluble guanylate cyclase by arachidonic acid requires absence of enzyme-bound heme. Biochim Biophys Acta. 1987; 928(2):160-70. DOI: 10.1016/0167-4889(87)90117-0. View

Galanello R, Stamatoyannopoulos G, Papayannopoulou T . Mechanism of Hb F stimulation by S-stage compounds. In vitro studies with bone marrow cells exposed to 5-azacytidine, Ara-C, or hydroxyurea. J Clin Invest. 1988; 81(4):1209-16. PMC: 329651. DOI: 10.1172/JCI113437. View

SIEVERS G, Hakli H, Luhtala J, TENHUNEN R . Optical and EPR spectroscopy studies on haem arginate, a new compound used for treatment of porphyria. Chem Biol Interact. 1987; 63(2):105-14. DOI: 10.1016/0009-2797(87)90091-3. View

Fibach E, Manor D, OPPENHEIM A, Rachmilewitz E . Proliferation and maturation of human erythroid progenitors in liquid culture. Blood. 1989; 73(1):100-3. View

Abraham N, Mitrione S, Hodgson W, Levere R, Shibahara S . Expression of heme oxygenase in hemopoiesis. Adv Exp Med Biol. 1988; 241:97-116. DOI: 10.1007/978-1-4684-5571-7_13. View

Kaplan S, Billiar T, Curran R, Zdziarski U, Simmons R, Basford R . Inhibition of chemotaxis Ng-monomethyl-L-arginine: a role for cyclic GMP. Blood. 1989; 74(6):1885-7. View

Nakane M, Arai K, SAHEKI S, Kuno T, Buechler W, Murad F . Molecular cloning and expression of cDNAs coding for soluble guanylate cyclase from rat lung. J Biol Chem. 1990; 265(28):16841-5. View

Beasley D, Schwartz J, Brenner B . Interleukin 1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. J Clin Invest. 1991; 87(2):602-8. PMC: 296349. DOI: 10.1172/JCI115036. View

McDonagh K, Lin H, Lowrey C, Bodine D, Nienhuis A . The upstream region of the human gamma-globin gene promoter. Identification and functional analysis of nuclear protein binding sites. J Biol Chem. 1991; 266(18):11965-74. View

10.

Ikuta T, Kan Y . In vivo protein-DNA interactions at the beta-globin gene locus. Proc Natl Acad Sci U S A. 1991; 88(22):10188-92. PMC: 52893. DOI: 10.1073/pnas.88.22.10188. View

11.

Jane S, Ney P, Vanin E, Gumucio D, Nienhuis A . Identification of a stage selector element in the human gamma-globin gene promoter that fosters preferential interaction with the 5' HS2 enhancer when in competition with the beta-promoter. EMBO J. 1992; 11(8):2961-9. PMC: 556778. DOI: 10.1002/j.1460-2075.1992.tb05366.x. View

12.

Rodgers G . Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience. Semin Oncol. 1992; 19(3 Suppl 9):67-73. View

13.

Leder A, Orkin S, Leder P . Differentiation of erythroleukemic cells in the presence of inhibitors of DNA synthesis. Science. 1975; 190(4217):893-4. DOI: 10.1126/science.1059262. View

14.

Ross J, Sautner D . Induction of globin mRNA accumulation by hemin in cultured erythroleukemic cells. Cell. 1976; 8(4):513-20. DOI: 10.1016/0092-8674(76)90219-1. View

15.

Rutherford T, Clegg J, Weatherall D . K562 human leukaemic cells synthesise embryonic haemoglobin in response to haemin. Nature. 1979; 280(5718):164-5. DOI: 10.1038/280164a0. View

16.

Groudine M, Weintraub H . Activation of globin genes during chicken development. Cell. 1981; 24(2):393-401. DOI: 10.1016/0092-8674(81)90329-9. View

17.

KRUH J . Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem. 1982; 42(2):65-82. DOI: 10.1007/BF00222695. View

18.

Ley T, DESIMONE J, Anagnou N, Keller G, Humphries R, Turner P . 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. N Engl J Med. 1982; 307(24):1469-75. DOI: 10.1056/NEJM198212093072401. View

19.

Gerzer R, Hamet P, Ross A, Lawson J, Hardman J . Calcium-induced release from platelet membranes of fatty acids that modulate soluble guanylate cyclase. J Pharmacol Exp Ther. 1983; 226(1):180-6. View

20.

Dean A, Ley T, Humphries R, Fordis M, Schechter A . Inducible transcription of five globin genes in K562 human leukemia cells. Proc Natl Acad Sci U S A. 1983; 80(18):5515-9. PMC: 384288. DOI: 10.1073/pnas.80.18.5515. View